Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Диагностика, профилактика и лечение хронической сердечной недостаточности: что должен знать врач-терапевт амбулаторного звена здравоохранения
Диагностика, профилактика и лечение хронической сердечной недостаточности: что должен знать врач-терапевт амбулаторного звена здравоохранения
Ларина В.Н., Чукаева И.И., Бубнова М.Г. Диагностика, профилактика и лечение хронической сердечной недостаточности: что должен знать врач-терапевт амбулаторного звена здравоохранения (по рекомендациям Европейского общества кардиологов по диагностике и лечению острой и хронической сердечной недостаточности 2016 г.). КардиоСоматика. 2017; 8 (3): 29–38.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье в реферативной форме представлены основные положения рекомендаций Европейского общества кардиологов и Ассоциации по сердечной недостаточности 2016 г. Представлена новая классификация, освещены подходы к диагностике и фармакологическому лечению хронической сердечной недостаточности, уделено внимание профилактике развития клинически выраженной сердечной недостаточности и мультидисциплинарному подходу при ведении больных с этой патологией.
Ключевые слова: хроническая сердечная недостаточность, рекомендации, лечение.
Key words: chronic heart failure, recommendations, treatment.
Ключевые слова: хроническая сердечная недостаточность, рекомендации, лечение.
________________________________________________
Key words: chronic heart failure, recommendations, treatment.
Полный текст
Список литературы
1. Ponikowski P, Voors A, Anker S et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016. DOI: 10.1093/eurheartj/ehw128
2. Lam C, Solomon S. The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). Eur J Heart Fail 2014; 16: 1049–55.
3. Thibodeau J, Turer A, Gualano S et al. Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail 2014; 2: 24–31.
4. Wright J, Williamson J, Whelton P et al. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103–16.
5. McMurray J, Packer M, Desai A and PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004.
6. Nieuwlaat R, Eurling LW, Cleland JG et al. Atrial fibrillation and heart failure in cardiology practice. Results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 2009; 53: 1690.
7. Connolly S, Ezekowitz M, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 17; 361 (12): 1139–51.
8. Patel M, Mahaffey K, Garg J et al, and the ROCKET AF Steering Committee, for the ROCKET AF Investigator. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883–91.
9. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fib- rillation. N Engl J Med 2011; 365 (11): 981–92.
10. McMurray JJV, Ezekowitz J A, Lewis BS et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation insights from the ARISTOTLE trial. Circ Heart Fail 2013; 6 (3): 451–60.
11. Connolly S, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 3 (364, 9): 806–17.
12. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17 (10): 1467–507.
13. Frost C, Nepal S, Wang J et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013; 76 (5): 776–86.
2. Lam C, Solomon S. The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). Eur J Heart Fail 2014; 16: 1049–55.
3. Thibodeau J, Turer A, Gualano S et al. Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail 2014; 2: 24–31.
4. Wright J, Williamson J, Whelton P et al. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103–16.
5. McMurray J, Packer M, Desai A and PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004.
6. Nieuwlaat R, Eurling LW, Cleland JG et al. Atrial fibrillation and heart failure in cardiology practice. Results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 2009; 53: 1690.
7. Connolly S, Ezekowitz M, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 17; 361 (12): 1139–51.
8. Patel M, Mahaffey K, Garg J et al, and the ROCKET AF Steering Committee, for the ROCKET AF Investigator. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883–91.
9. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fib- rillation. N Engl J Med 2011; 365 (11): 981–92.
10. McMurray JJV, Ezekowitz J A, Lewis BS et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation insights from the ARISTOTLE trial. Circ Heart Fail 2013; 6 (3): 451–60.
11. Connolly S, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 3 (364, 9): 806–17.
12. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17 (10): 1467–507.
13. Frost C, Nepal S, Wang J et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013; 76 (5): 776–86.
2. Lam C, Solomon S. The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). Eur J Heart Fail 2014; 16: 1049–55.
3. Thibodeau J, Turer A, Gualano S et al. Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail 2014; 2: 24–31.
4. Wright J, Williamson J, Whelton P et al. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103–16.
5. McMurray J, Packer M, Desai A and PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004.
6. Nieuwlaat R, Eurling LW, Cleland JG et al. Atrial fibrillation and heart failure in cardiology practice. Results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 2009; 53: 1690.
7. Connolly S, Ezekowitz M, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 17; 361 (12): 1139–51.
8. Patel M, Mahaffey K, Garg J et al, and the ROCKET AF Steering Committee, for the ROCKET AF Investigator. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883–91.
9. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fib- rillation. N Engl J Med 2011; 365 (11): 981–92.
10. McMurray JJV, Ezekowitz J A, Lewis BS et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation insights from the ARISTOTLE trial. Circ Heart Fail 2013; 6 (3): 451–60.
11. Connolly S, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 3 (364, 9): 806–17.
12. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17 (10): 1467–507.
13. Frost C, Nepal S, Wang J et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013; 76 (5): 776–86.
________________________________________________
2. Lam C, Solomon S. The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). Eur J Heart Fail 2014; 16: 1049–55.
3. Thibodeau J, Turer A, Gualano S et al. Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail 2014; 2: 24–31.
4. Wright J, Williamson J, Whelton P et al. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103–16.
5. McMurray J, Packer M, Desai A and PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004.
6. Nieuwlaat R, Eurling LW, Cleland JG et al. Atrial fibrillation and heart failure in cardiology practice. Results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 2009; 53: 1690.
7. Connolly S, Ezekowitz M, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 17; 361 (12): 1139–51.
8. Patel M, Mahaffey K, Garg J et al, and the ROCKET AF Steering Committee, for the ROCKET AF Investigator. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883–91.
9. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fib- rillation. N Engl J Med 2011; 365 (11): 981–92.
10. McMurray JJV, Ezekowitz J A, Lewis BS et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation insights from the ARISTOTLE trial. Circ Heart Fail 2013; 6 (3): 451–60.
11. Connolly S, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 3 (364, 9): 806–17.
12. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17 (10): 1467–507.
13. Frost C, Nepal S, Wang J et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013; 76 (5): 776–86.
Авторы
В.Н.Ларина*1, И.И.Чукаева1, М.Г.Бубнова2
1 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
2 ФГБУ «Национальный медицинский исследовательский центр профилактической медицины» Минздрава России. 101990, Россия, Москва, Петроверигский пер., д. 10, стр. 3
*larinav@mail.ru
1 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
2 National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation. 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3
*larinav@mail.ru
1 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
2 ФГБУ «Национальный медицинский исследовательский центр профилактической медицины» Минздрава России. 101990, Россия, Москва, Петроверигский пер., д. 10, стр. 3
*larinav@mail.ru
________________________________________________
1 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
2 National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation. 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3
*larinav@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.